Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Cationic derivative of dextran reverses anticoagulant activity of unfractionated heparin in animal models of arterial and venous thrombosis.

Kalaska B, Sokolowska E, Kaminski K, Szczubialka K, Kramkowski K, Mogielnicki A, Nowakowska M, Buczko W.

Eur J Pharmacol. 2012 Jul 5;686(1-3):81-9. doi: 10.1016/j.ejphar.2012.04.037. Epub 2012 May 2.

PMID:
22579410
2.

In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative.

Kuziej J, Litinas E, Hoppensteadt DA, Liu D, Walenga JM, Fareed J, Jeske W.

Clin Appl Thromb Hemost. 2010 Aug;16(4):377-86. doi: 10.1177/1076029610366439. Epub 2010 May 11.

PMID:
20460347
3.

Nonclinical evaluation of novel cationically modified polysaccharide antidotes for unfractionated heparin.

Kalaska B, Kaminski K, Sokolowska E, Czaplicki D, Kujdowicz M, Stalinska K, Bereta J, Szczubialka K, Pawlak D, Nowakowska M, Mogielnicki A.

PLoS One. 2015 Mar 17;10(3):e0119486. doi: 10.1371/journal.pone.0119486. eCollection 2015.

4.

Neutralase reverses the anti-coagulant but not the anti-thrombotic activity of heparin in a rabbit model of venous thrombosis.

Silver PJ, Broughton R, Bouthillier J, Quinn TA, Wallace AM, Weishaar RE.

Thromb Res. 1998 Aug 1;91(3):143-50.

PMID:
9733158
5.
6.

Antagonism of SR 90107A/Org 31540-induced bleeding by protamine sulfate in rats and mice.

Bernat A, Hoffmann P, Herbert JM.

Thromb Haemost. 1996 Nov;76(5):715-9.

PMID:
8950779
7.

A novel protamine variant reversal of heparin anticoagulation in human blood in vitro.

Hulin MS, Wakefield TW, Andrews PC, Wrobleski SK, Stoneham MD, Doyle AR, Zelenock GB, Jacobs LA, Shanley CJ, TenCate VM, Stanley JC.

J Vasc Surg. 1997 Dec;26(6):1043-8.

8.

Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.

Mochizuki T, Olson PJ, Szlam F, Ramsay JG, Levy JH.

Anesth Analg. 1998 Oct;87(4):781-5.

PMID:
9768770
9.

Anticoagulant effects of protamine sulfate in a canine model.

Kresowik TF, Wakefield TW, Fessler RD 2nd, Stanley JC.

J Surg Res. 1988 Jul;45(1):8-14.

10.

Heparin from bovine intestinal mucosa: glycans with multiple sulfation patterns and anticoagulant effects.

Tovar AM, Capillé NV, Santos GR, Vairo BC, Oliveira SN, Fonseca RJ, Mourão PA.

Thromb Haemost. 2012 May;107(5):903-15. doi: 10.1160/TH-11-07-0518. Epub 2012 Mar 22.

PMID:
22437650
11.

Fucosylated chondroitin sulfate as a new oral antithrombotic agent.

Fonseca RJ, Mourão PA.

Thromb Haemost. 2006 Dec;96(6):822-9.

PMID:
17139379
12.

Utility of anticoagulant drugs in vascular thrombosis: electron microscopic and biophysical study.

Sawyer PN, Stanczewski B, Pomerance A, Stoner G, Srinivasan S.

Surgery. 1973 Aug;74(2):263-75. No abstract available.

PMID:
4717662
13.

Platelet factor 4 efficiently reverses heparin anticoagulation in the rat without adverse effects of heparin-protamine complexes.

Cook JJ, Niewiarowski S, Yan Z, Schaffer L, Lu W, Stewart GJ, Mosser DM, Myers JA, Maione TE.

Circulation. 1992 Mar;85(3):1102-9.

PMID:
1537108
14.

Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist.

Cushing DJ, Cooper WD, Cohen ML, McVoy JR, Sobel M, Harris RB.

Eur J Pharmacol. 2010 Jun 10;635(1-3):165-70. doi: 10.1016/j.ejphar.2010.03.016. Epub 2010 Mar 20.

PMID:
20307530
15.

Neutralization of the antithrombotic effects of heparin and Fraxiparin by protamine sulfate.

Racanelli A, Fareed J.

Thromb Res. 1992 Nov 1;68(3):211-22.

PMID:
1471069
16.

Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation.

Massonnet-Castel S, Pelissier E, Bara L, Terrier E, Abry B, Guibourt P, Swanson J, Jaulmes B, Carpentier A, Samama M.

Haemostasis. 1986;16(2):139-46.

PMID:
3710291
17.

[Neutralization of low molecular weight heparin Kabi 2165 by protamine chloride].

Harenberg J, Giese C, Knödler A, Zimmermann R, Schettler G.

Klin Wochenschr. 1986 Nov 17;64(22):1171-5. German.

PMID:
3807263
18.

Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients.

Gale AJ, Elias DJ, Averell PM, Teirstein PS, Buck M, Brown SD, Polonskaya Z, Udit AK, Finn MG.

Thromb Res. 2011 Oct;128(4):e9-13. doi: 10.1016/j.thromres.2011.03.021. Epub 2011 Apr 14.

19.

Alteration of blood clotting and lung damage by protamine are avoided using the heparin and polyphosphate inhibitor UHRA.

Kalathottukaren MT, Abraham L, Kapopara PR, Lai BF, Shenoi RA, Rosell FI, Conway EM, Pryzdial EL, Morrissey JH, Haynes CA, Kizhakkedathu JN.

Blood. 2017 Mar 9;129(10):1368-1379. doi: 10.1182/blood-2016-10-747915. Epub 2016 Dec 29.

PMID:
28034889
20.

Effect of Sulfation and Molecular Weight on Anticoagulant Activity of Dextran.

Drozd NN, Logvinova YS, Torlopov MA, Udoratina EV.

Bull Exp Biol Med. 2017 Feb;162(4):462-465. doi: 10.1007/s10517-017-3640-2. Epub 2017 Feb 27.

PMID:
28243911

Supplemental Content

Support Center